Zucara Therapeutics
Vancouver
About Zucara Therapeutics
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled. It has demonstrated potential to specifically block somatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $53.8M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2025)
- Website: zucara.ca
Industries & Categories
Biotechnology, Diabetes, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/zucara-therapeutics-94907 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.